Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
- PMID: 19671735
- DOI: 10.1158/1535-7163.MCT-09-0366
Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
Erratum in
- Mol Cancer Ther. 2012 Jun;11(6):1381
Abstract
Microtubules are important cellular targets for anticancer therapy because of their key role in mitosis. Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in apoptosis. In spite of their antitumor activity, innate or acquired drug resistance to MTIs such as the taxanes is common, limiting their overall clinical efficacy. Further insight into the mechanisms of action of microtubule-targeting drugs has lead to the discovery of novel agents that may provide higher efficacy with limited toxicity and help overcome resistance to conventional MTIs. This review will focus on the different mechanisms of action of MTIs, potential factors related to resistance and tolerability, and will discuss the recent approval as well as the development of new antineoplastic agents.
Similar articles
-
Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.Ann Oncol. 2007 Jul;18 Suppl 5:v3-8. doi: 10.1093/annonc/mdm172. Ann Oncol. 2007. PMID: 17656560 Review.
-
Microtubule active agents: beyond the taxane frontier.Clin Cancer Res. 2008 Nov 15;14(22):7167-72. doi: 10.1158/1078-0432.CCR-08-0169. Clin Cancer Res. 2008. PMID: 19010832 Review.
-
Development of other microtubule-stabilizer families: the epothilones and their derivatives.Anticancer Drugs. 2014 May;25(5):599-609. doi: 10.1097/CAD.0000000000000071. Anticancer Drugs. 2014. PMID: 24398663 Review.
-
Microtubules: a dynamic target in cancer therapy.IUBMB Life. 2008 Mar;60(3):165-70. doi: 10.1002/iub.25. IUBMB Life. 2008. PMID: 18380008 Review.
-
Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.Curr Top Med Chem. 2017;17(22):2523-2537. doi: 10.2174/1568026617666170104145640. Curr Top Med Chem. 2017. PMID: 28056738 Review.
Cited by
-
Beyond the Paclitaxel and Vinca Alkaloids: Next Generation of Plant-Derived Microtubule-Targeting Agents with Potential Anticancer Activity.Cancers (Basel). 2020 Jun 29;12(7):1721. doi: 10.3390/cancers12071721. Cancers (Basel). 2020. PMID: 32610496 Free PMC article. Review.
-
A screen for kinetochore-microtubule interaction inhibitors identifies novel antitubulin compounds.PLoS One. 2010 Jul 15;5(7):e11603. doi: 10.1371/journal.pone.0011603. PLoS One. 2010. PMID: 20657644 Free PMC article.
-
The Novel Nature Microtubule Inhibitor Ivalin Induces G2/M Arrest and Apoptosis in Human Hepatocellular Carcinoma SMMC-7721 Cells In Vitro.Medicina (Kaunas). 2019 Aug 12;55(8):470. doi: 10.3390/medicina55080470. Medicina (Kaunas). 2019. PMID: 31409007 Free PMC article.
-
Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents.Invest New Drugs. 2012 Feb;30(1):164-75. doi: 10.1007/s10637-010-9547-7. Epub 2010 Oct 2. Invest New Drugs. 2012. PMID: 20890633
-
5-arylalkynyl-2-benzoyl thiophene: a novel microtubule inhibitor exhibits antitumor activity without neurological toxicity.Am J Cancer Res. 2022 Jan 15;12(1):229-246. eCollection 2022. Am J Cancer Res. 2022. PMID: 35141015 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
